Which Patients Might Benefit from Postmastectomy Radiotherapy in Breast Cancer Patients with T1-2 Tumor and 1-3 Axillary Lymph Nodes Metastasis?

다국어 초록 (Multilingual Abstract)

Purpose This study compared the clinical outcomes of T1-2N1 breast cancer patients with and without postmastectomy radiotherapy (PMRT). Risk factors for loco-regional recurrence (LRR) were identified in order to define a subgroup of patients who might benefit from PMRT.

Materials and Methods Of 110 T1-2N1 breast cancer patients who underwent mastectomy from January 1994 through December 2009, 32 patients underwent PMRT and 78 patients did not. Treatment outcomes and risk factors for LRR were analyzed.

Results The 5- and 10-year LRR rates were both 6.2% in the PMRT group, and 10.4% and 14.6% in the no-PMRT group (p=0.336). In addition, no significant differences in distant metastasis-free survival (DMFS) or overall survival (OS) were observed between patients receiving and not receiving PMRT. In multivariate analysis, factors associated with higher LRR rates included grade 3 disease, extracapsular extension (ECE), and triple negative subtype. Patients who had one or more risk factors for LRR were defined as a high-risk patient group. In the high-risk group, both 5- and 10-year LRR rates for patients who underwent PMRT was 18.2%, and LRR rates of 21.4% at five years and 36.6% at 10 years were observed for patients who did not undergo PMRT (p=0.069).

Conclusion PMRT in T1-2N1 breast cancer patients should be considered according to several prognostic factors in addition to T and N stage. Findings of our study indicated that PMRT did not improve LRR, DMFS, or OS in T1-2N1 breast cancer patients. However,in a subgroup of patients with grade 3 disease, ECE, or triple negative subtype, PMRT might be beneficial.

참고문헌 (Reference)

1 Pierce LJ, "Treatment guidelines and techniques in delivery of postmastectomy radiotherapy in management of operable breast cancer" 30 : 117-124, 2001

2 Fernando IN, "The role of radiotherapy in patients undergoing mastectomy for carcinoma of the breast" 12 : 158-165, 2000

3 Duraker N, "Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis" 42 : 601-608, 2012

4 Truong PT, "Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional postmastectomy radiotherapy" 170 : 1263-1273, 2004

5 Truong PT, "Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy" 61 : 1337-1347, 2005

6 Kunkler IH, "Russell NS;MRC/ EORTC (BIG 2-04) SUPREMO Trial Management Group. Elucidating the role of chest wall irradiation in ‘intermediaterisk’ breast cancer: the MRC/EORTC SUPREMO trial" 20 : 31-34, 2008

7 Wallgren A, "Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII" 21 : 1205-1213, 2003

8 Overgaard M, "Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial" 337 : 949-955, 1997

9 Overgaard M, "Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet" 353 : 1641-1648, 1999

10 Recht A, "Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology" 19 : 1539-1569, 2001

11 Fowble B, "Postmastectomy radiation in patients with one to three positive axillary nodes receiving adjuvant chemotherapy: an unresolved issue" 9 : 230-240, 1999

12 Smith BD, "Postmastectomy radiation and mortality in women with T1-2 node-positive breast cancer" 23 : 1409-1419, 2005

13 Cosar R, "Postmastectomy irradiation in breast in breast cancer patients with T1-2 and 1-3 positive axillary lymph nodes: is there a role for radiation therapy" 6 : 28-, 2011

14 Marks LB, "One to three versus four or more positive nodes and postmastectomy radiotherapy: time to end the debate" 26 : 2075-2077, 2008

15 Ragaz J, "Locoregional radiation therapy in patients with highrisk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial" 97 : 116-126, 2005

16 Trovo M, "Locoregional failure in early-stage breast cancer patients treated with radical mastectomy and adjuvant systemic therapy: which patients benefit from postmastectomy irradiation" 83 : e153-e157, 2012

17 Overgaard M, "Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials" 82 : 247-253, 2007

18 Sotiriou C, "Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis" 98 : 262-272, 2006

19 Kreike B, "Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breastconserving therapy" 12 : 5705-5712, 2006

20 Sorlie T, "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications" 98 : 10869-10874, 2001

21 Whelan TJ, "Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis" 18 : 1220-1229, 2000

22 Nguyen PL, "Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy" 26 : 2373-2378, 2008

23 Sotiriou C, "Breast cancer classification and prognosis based on gene expression profiles from a population-based study" 100 : 10393-10398, 2003

24 Ragaz J, "Adjuvant radiotherapy and chemotherapy in nodepositive premenopausal women with breast cancer" 337 : 956-962, 1997

25 Taylor ME, "ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncologybreast" 73 : 997-1002, 2009